Clinical Trials Logo

Arthritis clinical trials

View clinical trials related to Arthritis.

Filter by:

NCT ID: NCT03365856 Not yet recruiting - Clinical trials for Rheumatoid Arthritis

Remission in Rheumatoid Arthritis in the Asian-Pacific Region

Start date: January 1, 2018
Phase: N/A
Study type: Observational

This study is the multi-center, open and cross-sectional study of RA remission in Asia Pacific region. The objectives is to explore remission rate of RA patients in different countries in the Asian-Pacific area using different criteria of remission (DAS28, CDAI, SDAI, ACR/EULA remission criteria, RAPID3 and Clin28) and investigate the associated factors of remission in RA patients.

NCT ID: NCT03357471 Completed - Clinical trials for Active Psoriatic Arthritis

Study to Test the Safe and Effective Use of an e-Device for the Self-injection of Certolizumab Pegol Solution by Subjects With Moderate to Severe Active Rheumatoid Arthritis, Active Ankylosing Spondylitis, Active Psoriatic Arthritis, or Moderately to Severely Active Crohn's Disease

Start date: November 3, 2017
Phase: Phase 3
Study type: Interventional

The purpose of the study is to evaluate the ability of subjects who are already prescribed Certolizumab Pergol therapy and have been self injecting with prefilled syringes for at least the previous three months, to safely and effectively self-inject Certolizumab Pegol (CZP) using the e-Device and to evaluate the post-use structural integrity of used devices and cassettes via visual examination.

NCT ID: NCT03355872 Completed - Clinical trials for Rheumatoid Arthritis

A Randomised, Double-blind, Phase I/II Study to Evaluate the PK, PD, Safety, and Efficacy Between HLX01 and Rituximab in Patients With Moderate to Severe Rheumatoid Arthritis and Inadequate Response to Treatment With DMARDs

Start date: February 2016
Phase: Phase 1/Phase 2
Study type: Interventional

To compare the PK profiles of HLX01 and Rituximab in Chinese patients with moderate to severe rheumatoid arthritis.

NCT ID: NCT03348046 Completed - Clinical trials for Rheumatoid Arthritis

Safety Study of Remsima® (Infliximab) in Rheumatoid Arthritis Patients in Jordan

PASSRRA
Start date: March 23, 2017
Phase:
Study type: Observational

The purpose of this observational study is to assess the safety and effectiveness of biosimilar Infliximab in patients with rheumatoid arthritis(RA) in Jordan where no visits or intervention(s) additional to the daily practice will be performed

NCT ID: NCT03347110 Completed - Psoriatic Arthritis Clinical Trials

A Study to Evaluate the Long-Term Safety and Efficacy of Bimekizumab in Subjects With Psoriatic Arthritis

BE ACTIVE 2
Start date: November 22, 2017
Phase: Phase 2
Study type: Interventional

This is a study to assess the long-term safety and tolerability of bimekizumab in subjects with psoriatic arthritis

NCT ID: NCT03346590 Not yet recruiting - Clinical trials for Active Rheumatoid Arthritis

Evolution of Total Energy Expenditure and Its Various Components in Active Rheumatoid Arthritis (RA)Treated With Anti-TNF Agents and Comparison With Healthy Subjects

Start date: November 30, 2017
Phase: N/A
Study type: Interventional

Chronic inflammation in rheumatoid arthritis is associated with adiposity, sarcopenia, cachexia, reduced activity due to functional impairment, and anti-inflammatory drugs. Patients frequently gain weight when taking anti-tumor necrosis factor (TNF) medication, prompting questions about the underlying mechanism and long-term cardiovascular and metabolic tolerance associated with these drugs The primary objective of this study is to analyze the impact of anti-TNF treatment during the first year of administration on the energy metabolism of patients suffering from RA, assessed as an absolute value (before-after) and in comparison with a standard measured in healthy matched subjects.

NCT ID: NCT03345186 Completed - Arthritis Clinical Trials

A Nurse Led Patient Management Programme to Improve Outcomes in Gout

BONUS
Start date: April 1, 2019
Phase: N/A
Study type: Interventional

This study evaluates the addition of a structured nurse led patient management programme to standard of care in gout patients. Half of the patient will receive the nurse led programme in addition to standard of care and the other half will receive standard of care only.

NCT ID: NCT03343171 Active, not recruiting - Osteoarthritis Clinical Trials

Continuum Ceramic on Ceramic Bearing Post Market Clinical Follow-Up Study

Start date: September 15, 2010
Phase:
Study type: Observational

The primary objective of this study is to obtain implant survivorship and clinical outcome data for the commercially available Zimmer® Continuumâ„¢ Ceramic-on-Ceramic Bearing System when used in primary hip arthroplasty. This will be done by analysis of standard scoring systems, radiographs and adverse event records. Data will be used to monitor pain, mobility and survivorship, and to confirm the safety and efficacy of the Continuum Ceramic-on-Ceramic Bearing System.

NCT ID: NCT03339089 Completed - Psoriasis Clinical Trials

Real-world Effectiveness of Adalimumab on Health Outcomes in Chinese Patients With Immune-Mediated Inflammatory Diseases

ADMIT
Start date: May 18, 2018
Phase:
Study type: Observational

The objective of this study is to evaluate the effect of adalimumab on health outcomes in participants with rheumatoid arthritis, ankylosing spondylitis and plaque psoriasis.

NCT ID: NCT03337815 Recruiting - Clinical trials for Rheumatoid Arthritis

A Specification Clinical Application Research of Tripterygium Wilfordii Treating Rheumatoid Arthritis

Start date: October 28, 2017
Phase: Phase 2/Phase 3
Study type: Interventional

Rheumatoid Arthritis (RA) is an autoimmune disease that results in a chronic inflammatory disorder that may affect many synovial joints, and may cause serious disability. It has been confirmed that Tripterygium Wilfordii has effects of anti-inflammatory, immunosuppressive and cartilage protection. This is a multicenter ,double Blind, randomized study to evaluated the efficacy and safety of Tripterygium Wilfordii in treating of patients with rheumatoid arthritis (RA) and establish a prediction model for Tripterygium Wilfordii response of rheumatoid arthritis (RA).